InvestorsHub Logo
Followers 3
Posts 276
Boards Moderated 0
Alias Born 12/21/2022

Re: None

Thursday, 07/27/2023 6:48:10 PM

Thursday, July 27, 2023 6:48:10 PM

Post# of 3283
From today's Takeda earning call. "Following a planned interim analysis, the Phase 3 EXCLAIM-2 trial was stopped for futility. The trial compared EXKIVITY monotherapy to chemotherapy in first line, non-small cell lung cancer with exon 20 insertion mutations. We will be engaging with regulators required regarding these data and determining next steps for the program." So, mobocertinib doesn't work better than chemo.